Does Kevzara Work for Rheumatoid Arthritis?
Kevzara (sarilumab) is FDA-approved for treating moderate to severe rheumatoid arthritis (RA) in adults who have not responded well to one or more tumor necrosis factor (TNF) inhibitors. It works by blocking interleukin-6 (IL-6) receptors, reducing inflammation and joint damage in RA patients.[1]
Clinical trials show it reduces symptoms and slows disease progression. In the MOBILITY study, 58% of patients on Kevzara 200 mg plus methotrexate achieved ACR20 response (20% improvement in RA signs/symptoms) at week 24, compared to 44% on placebo plus methotrexate. About 30% hit ACR50 and 17% ACR70. Radiographic data confirmed it inhibited joint damage over two years.[2]
Real-world evidence supports these results, with patients reporting less pain and better function, though response varies by individual factors like disease duration and prior treatments.
How Does Kevzara Compare to Other RA Drugs?
Kevzara outperforms placebo in head-to-head trials against adalimumab (Humira). In the MONARCH study, more Kevzara patients (44% vs 33%) reached low disease activity or remission at week 24, without needing methotrexate.[3]
| Drug | Mechanism | ACR20 Response Rate (Key Trial) | Common Use Case |
|------|-----------|---------------------------------|-----------------|
| Kevzara | IL-6 inhibitor | 58% (MOBILITY)[2] | TNF non-responders |
| Humira | TNF inhibitor | 33% (MONARCH vs Kevzara)[3] | First-line biologic |
| Xeljanz | JAK inhibitor | 65-70% (ORAL Standard)[4] | Oral alternative |
| Rituxan | B-cell depletor | 54% (REFLEX)[5] | Seropositive RA |
Kevzara suits patients needing an injectable biologic after TNF failure, but JAK inhibitors like Xeljanz may work faster for some.
What Side Effects Do RA Patients Experience with Kevzara?
Common issues include upper respiratory infections (29%), injection site reactions (10%), and elevated liver enzymes. Serious risks: infections (like tuberculosis), gastrointestinal perforations, and neutropenia. Black box warning for infections and malignancy risk. Monitor lipids and liver function regularly.[1]
Patients often report fewer infections than with TNF inhibitors but more than with some oral options.
How Long Until Kevzara Starts Working for RA?
Many notice improvement in pain and stiffness within 2-4 weeks. Full ACR responses peak around 12-24 weeks. If no benefit by week 12, doctors reassess.[2]
Who Makes Kevzara and When Do Patents Expire?
Sanofi and Regeneron co-developed and market Kevzara. U.S. patents expire around 2032, with some formulation patents to 2036. No biosimilars approved yet. Check DrugPatentWatch.com for latest challenges and expiry details.[6]
Can Kevzara Help If Other RA Treatments Failed?
Yes, especially post-TNF. In trials, it worked in 40-50% of TNF non-responders. Not for mild RA or monotherapy without methotrexate trial first.[1]
Sources
[1]: FDA Kevzara Label
[2]: New England Journal of Medicine - MOBILITY
[3]: Annals of the Rheumatic Diseases - MONARCH
[4]: New England Journal of Medicine - ORAL Standard
[5]: Arthritis & Rheumatology - REFLEX
[6]: DrugPatentWatch.com - Kevzara